Related Experiment Video
Updated: Mar 11, 2026
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Development of crizotinib, a rationally designed tyrosine kinase inhibitor for non-small cell lung cancer
Candice C Poon1, John J Kelly1
1Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada.
Abstract:
Non-small cell lung cancer (NSCLC) is the number one cause of global mortality. Despite aggressive treatment, the prognosis is dismal. Patients with advanced NSCLC have a median survival of 4 months from the time of diagnosis. Fortunately, molecularly based approaches to drug discovery have yielded a tyrosine kinase inhibitor, crizotinib, which significantly prolongs median progression-free survival in a subset of patients. Although initial clinical trial results demonstrate crizotinib has a promising role to play in NSCLC treatment, development of resistance leaves much to be elucidated about how to effectively combat this deadly disease. In this review, we follow the discovery and development of crizotinib from bench to bedside and provide an example of successful bottom-up drug design. Then, we explore the clinical trial results that fast-tracked its eventual use as a frontline therapy for sensitive NSCLC patients and the development of resistance. Lastly, we discuss the potential for future uses of crizotinib both within and beyond NSCLC.
Insights
Crizotinib, a targeted therapy for non-small cell lung cancer (NSCLC), shows promise but faces resistance challenges. Further research is needed to optimize its use and combat this deadly disease effectively.
Area of Science:
- Oncology
- Pharmacology
- Drug Discovery
Background:
- Non-small cell lung cancer (NSCLC) remains a leading cause of cancer mortality with poor prognosis for advanced stages.
- Current treatments offer limited survival benefits, highlighting the need for novel therapeutic strategies.
Purpose of the Study:
- To review the discovery and development of crizotinib, a tyrosine kinase inhibitor for NSCLC.
- To explore clinical trial outcomes, therapeutic resistance, and future applications of crizotinib.
Main Methods:
- Literature review focusing on crizotinib's journey from bench to bedside.
- Analysis of clinical trial data and research on resistance mechanisms.
Main Results:
- Crizotinib represents a successful example of targeted drug design, significantly improving progression-free survival in a subset of NSCLC patients.
- Clinical trials established crizotinib as a frontline therapy for sensitive NSCLC, but acquired resistance necessitates further investigation.
Conclusions:
- Crizotinib exemplifies successful targeted therapy in NSCLC, offering a paradigm for precision medicine.
- Understanding and overcoming resistance mechanisms are crucial for maximizing crizotinib's clinical benefit and exploring its broader therapeutic potential.
More Related Videos
10:49Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
02:34Inhibition of Cdk Activity